Interferon-Based Therapy Decreases Risks of Hepatocellular Carcinoma and Complications of Cirrhosis in Chronic Hepatitis C Patients

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Hsu, Ching Sheng ^a,b   Huang, Chun Jen ^a,b,c   Kao, Jia Horng ^d   Lin, Hans Hsienhong ^a,b   Chao, You Chen ^a,b   Fan, Yen Chun ^a   Tsai, Pei Shan ^e,f  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT INTERFERON;

ADULT; AGED; ARTICLE; ASCITES; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ESOPHAGUS VARICES BLEEDING; EVENT FREE SURVIVAL; FEMALE; HEALTH INSURANCE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; IMMUNOTHERAPY; INCIDENCE; INTERFERON BASED THERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; RISK ASSESSMENT; RISK REDUCTION; TAIWAN; TREATMENT OUTCOME; VIRUS DETECTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; BRAIN MAPPING; CASE-CONTROL STUDIES; CELL PHYSIOLOGICAL PHENOMENA; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; LONGITUDINAL STUDIES; MALE; MICE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEURAL NETWORKS (COMPUTER); NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; RATS;

EID: 84880714667     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070458     Document Type: Article

References (39)

1. Kao JH, Chen DS, (2000) Transmission of hepatitis C virus in Asia: past and present perspectives. J Gastroenterol Hepatol 15Suppl: E91-96.
2. Chen DS, (1995) Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp 25: 27-32.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB, (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
4. European Association for the Study of the Liver, (2011) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55: 245-264.
5. McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, et al. (2007) Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 22: 615-633.
6. Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, et al. (2005) Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 3: S89-91.
7. Gramenzi A, Andreone P, Fiorino S, Camma C, Giunta M, et al. (2001) Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 48: 843-848.
8. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, et al. (2009) Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 137: 1986-1994.
9. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, et al. (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359: 2429-2441.
10. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY,et al. (2011) Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 140: 840-849; quiz e812.
11. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, et al. (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131: 174-181.
12. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, et al. (1996) Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24: 141-147.
13. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, et al. (1998) Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 129: 94-99.
14. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, et al. (1998) Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 83: 901-909.
15. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. (2007) Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147: 677-684.
16. Manesis EK, Papatheodoridis GV, Touloumi G, Karafoulidou A, Ketikoglou J, et al. (2009) Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study. Aliment Pharmacol Ther 29: 1121-1130.
17. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, et al. (1998) Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28: 1687-1695.
18. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, et al. (1997) Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 27: 201-205.
19. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G, (2000) Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer 89: 53-59.
20. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ, (2001) Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 15: 689-698.
21. Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, et al. (2004) Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 39: 333-342.
22. Hu KQ, Tong MJ, (1999) The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29: 1311-1316.
23. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, et al. (1999) Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29: 1124-1130.
24. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, et al. (2006) A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antiviral therapy 11: 985-994.
25. Yu ML, Dai CY, Chen SC, Lee LP, Hsieh MY, et al. (2005) High versus standard doses interferon-alpha in the treatment of naive chronic hepatitis C patients in Taiwan: a 10-year cohort study. BMC Infect Dis 5: 27.
26. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, et al. (2010) Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 52: 652-657.
27. Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, et al. (2011) Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Antiviral therapy 16: 959-968.
28. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, et al. (1990) Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 162: 817-822.
29. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, et al. (2007) Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 106: 148-155.
30. Bureau of National Health Insurance, Department of Health, Executive Yuan, Taiwan. (2012) Universal Health Coverage in Taiwan. Available: http://www.nhi.gov.tw/Resource/webdata/21717_1_20120808UniversalHealthCoverage.pdf. Accessed 2013 May 20.
31. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, et al. (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatology international 4: 439-474.
32. Altman DG, (1998) Confidence intervals for the number needed to treat. Bmj 317: 1309-1312.
33. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, et al. (2010) Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 52: 833-844.
34. Yu ML, Huang CF, Dai CY, Huang JF, Chuang WL, (2007) Long-term effects of interferon-based therapy for chronic hepatitis C. Oncology. 72Suppl 1: 16-23.
35. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, et al. (2006) Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Journal of Viral Hepatitis 13: 409-414.
36. Younossi Z, Kallman J, Kincaid J, (2007) The effects of HCV infection and management on health-related quality of life. Hepatology 45: 806-816.
37. Bonis PA, Ioannidis JP, Cappelleri JC, Kaplan MM, Lau J, (1997) Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatology 26: 1035-1044.
38. Ingiliz P, Valantin MA, Preziosi P, Finzi L, Pais R, et al. (2012) Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis. Journal of Hepatology 56: 49-54.
39. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, et al. (2010) Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 52: 518-527.